![]() |
|
|
Vol. 292, Issue 2, 610-617, February 2000
Department of Pharmacology and Toxicology, University of Texas
Medical Branch, Galveston, Texas.
The influence of the 5-hydroxytryptamine1A agonist
8-hydroxy-2-(di-n-propylamino)tetralin (DPAT) on
locomotor hyperactivity induced by the acute and chronic administration
of cocaine was assessed. Horizontal activity was measured in the
periphery and center of an open field test enclosure equipped with
photobeams; vertical activity was also recorded. Peripheral
hyperactivity induced by an acute administration of cocaine (10 or 20 mg/kg) was significantly enhanced by 0.2 mg/kg DPAT. In contrast,
central and vertical activities were reduced in a dose-related
manner by DPAT (0.1 and 0.2 mg/kg); DPAT also suppressed central (0.2 mg/kg) and vertical (0.1 and 0.2 mg/kg) activities when administered alone. Similar observations were made on day 1 of chronic treatment with DPAT (0, 0.1, or 0.2 mg/kg) injected 15 min before an injection of
cocaine (0, 10, or 15 mg/kg) administered twice daily for 7 days. By
day 7 of repeated DPAT treatment, sensitization of DPAT-evoked peripheral activity developed, which contrasted with tolerance to the
central and vertical hypoactivity evoked by DPAT. Sensitization developed to the repeated treatment with 15 mg/kg cocaine but not 10 mg/kg cocaine. Interestingly, enhancements of all activity measures
were observed between days 1 and 7 in rats cotreated with DPAT plus
either dose of cocaine. This sensitization to DPAT plus cocaine was
expressed on challenge with DPAT and cocaine but not with cocaine
alone. The present study implies that the stimulation of
5-hydroxytryptamine1A receptors is capable of modulating the hyperactivity evoked by cocaine, possibly via modulation of the
mesoaccumbens dopamine circuit thought to mediate the behavioral effects of cocaine.
This article has been cited by other articles:
![]() |
A. Newman-Tancredi, D. Cussac, Y. Quentric, M. Touzard, L. Verriele, N. Carpentier, and M. J. Millan Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 815 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Bankson and K. A. Cunningham 3,4-Methylenedioxymethamphetamine (MDMA) as a Unique Model of Serotonin Receptor Function and Serotonin-Dopamine Interactions J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 846 - 852. [Abstract] [Full Text] |
||||
![]() |
M. J. Millan Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 853 - 861. [Abstract] [Full Text] |
||||